To determine the outcomes of metabolic and bariatric surgery (MBS) on patients diagnosed with breast cancer (BC), focusing on disease-free survival (DFS) and other oncologic outcomes such as subtype distribution and recurrence rates.
Key Findings:
MBS-group had a significantly lower BMI at the time of BC surgery compared to non-MBS-group (32.4 ± 6.5 kg/m2 vs 38.6 ± 4.1 kg/m2, p < 0.0001).
No significant differences in risk factors for BC between groups.
Higher incidence of ductal carcinoma in situ (DCIS) in the non-MBS group (20% vs 0%, p = 0.03).
MBS-group had significantly less Luminal-A type BC (34.4% vs 59.4%, p = 0.01) and more Luminal-B type BC (58.6% vs 27.6%, p = 0.001).
No significant differences in DFS (MBS 114 months vs non-MBS 146.6 months, p = 0.75) or recurrence rates, but subtype distribution changes may have clinical implications.
Interpretation:
MBS appears to alter the characteristics of breast cancer in patients with severe obesity, with significant differences in subtype distribution but no significant impact on disease-free survival or recurrence rates, suggesting a need for tailored management strategies.
Limitations:
Small sample size in the MBS group (29 patients).
Single-center study may limit generalizability.
Retrospective design may introduce selection bias, and potential confounding factors were not fully controlled.
Conclusion:
While MBS may influence breast cancer characteristics, it does not significantly affect disease-free survival or recurrence rates compared to non-MBS patients with severe obesity, highlighting the need for further research in this area.
